BCL2L1 and plasma cell myeloma: Human multiple myeloma (MM) cells as well as melanoma cells express high levels of BCL-XL [148, 149] and, accordingly, some of these malignant cells can be killed by treatment with inhibitors of BCL-XL, either on their own or more potently in combination with inhibitors of oncogenic kinases [150–152].